Abbott receives warning letter for Norvir promos

A pricing chart for Abbott's HIV therapy Norvir (ritonavir) misrepresents the dose and cost of therapy, a June 10 FDA 1warning letter states. The chart compares "a subtherapeutic dose of Norvir (100 mg once daily) to the labeled dosing regimens of other antiretroviral agents," FDA said. "The cost chart is false or misleading...because it claims that Norvir has the lowest daily cost of all antiretroviral drugs and minimizes the risks of Norvir." NIH is considering compulsory licensing for Norvir (2"The Pink Sheet" May 31, 2004, p. 3)...